Novo Nordisk Balances Weekly Insulin Debut in India with Aggressive Buyback as Korean Rivalry Heats Up
Published on 07/11/2026 at 07:14 | Redaktion boerse-global.de
Novo Nordisk is placing two big bets at once. On July 9, 2026, the Danish drugmaker launches Awiqli — a once-weekly basal insulin — in India, a market with more than 101 million diabetic patients. The product cuts annual injections from 365 to 52, a potential game-changer for adherence in a country where injection hesitancy is high. Simultaneously, the company is ploughing billions into its own shares: a buyback program that had already scooped up 23 million B-shares by July 3, at an average price of 270.32 Danish kroner each, for a total outlay of roughly 6.2 billion kroner. The twin moves — one aimed at expanding revenue, the other at shoring up per-share metrics — highlight management’s effort to restore investor confidence after a punishing 12-month stretch.
The stock closed Friday at €43.32, gaining 1.29% on the day. That nudged the weekly performance to a marginal loss of 0.41%, but the monthly picture is far brighter: the equity has climbed 16.78% in the past 30 days. The rebound from the March trough of €30.25 amounts to a recovery of more than 43%. Yet the longer view remains sobering. Novo Nordisk is still down 29.22% year-on-year and 3.04% since January. From its July 2025 peak of €61.20, the stock trades nearly 30% lower. Technically, the short-term trend looks constructive: the share price sits 9.64% above its 50-day moving average of €39.51 and 6.69% above its 200-day average of €40.60. The relative strength index at 66, however, warns that the rally has pushed into overbought territory, raising the risk of a near-term pullback.
Analyst opinion remains cautious despite the buyback spark. Of the 14 ratings on record, four are buys and ten are holds; there are no sell recommendations. HSBC recently raised its price target from 280 to 300 kroner but kept a “Hold” stance, citing the buyback as a key driver of recent gains but stopping short of outright bullishness. The split reflects a broader debate: proponents point to the structural support from net share reduction and the dividend, while skeptics fret over pricing pressure in the GLP-1 market and a slowdown in growth momentum.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
That competitive pressure is most visible in South Korea, where Novo Nordisk’s local unit has reorganized its obesity and diabetes divisions into one team — a move analysts interpret as a defensive shuffle against Eli Lilly. Lilly’s Mounjaro generated sales of 323.2 billion won in the first quarter, more than triple Wegovy’s 104 billion won. Novo Nordisk responded by slashing Wegovy’s wholesale price by roughly 40%, but the discount has not stemmed market share losses. In June, Lilly added extra high-dose versions of Mounjaro in Korea, widening the gap. Across the Pacific, the picture is different: CEO Mike Doustdar told CNBC that Wegovy now captures 65% of all new GLP-1 prescriptions in the United States, describing the situation as a “turnaround.” Still, Lilly’s Mounjaro and Zepbound are growing fast, ensuring the global duel remains intense.
The buyback remains a steady backstop. The current tranche, running from May 6, 2026, to February 1, 2027, authorizes repurchases of up to 11.2 billion kroner in B-shares. With 23 million shares already bought and a total of 40 million held in treasury — representing about 0.9% of share capital — Novo Nordisk is methodically reducing the float. Meanwhile, the pipeline extends beyond diabetes and obesity into cardiovascular disease and rare disorders, a diversification strategy that the Indian insulin launch supports. The next major test comes on August 5, when second-quarter results are due. Those numbers will reveal whether the operating momentum can keep pace with the recent stock rally or if the technical bounce has run ahead of the fundamentals.
Ad
Novo Nordisk Stock: New Analysis - 11 July
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
